Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Clinical trial NCT04336241 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04336241
- Sponsor
- Replimune, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-17
- Primary completion
- 2026-10-31
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.